| Catalog No. | HT009016 |
|---|
| Species reactivity | Human |
|---|
| Applications | Research Grade Biosimilar |
|---|
| Host species | Human |
|---|
| Isotype | IgG4-Kappa |
|---|
| Expression system | Mammalian Cells |
|---|
| Clonality | Monoclonal |
|---|
| Target | GFR-alpha-3, GDNF receptor alpha-3, GDNF family receptor alpha-3, GDNFR-alpha-3, GFRA3 |
|---|
| Concentration | 1mg/ml |
|---|
| Endotoxin level | Please contact the lab for this information. |
|---|
| Purity | >95% purity as determined by SDS-PAGE. |
|---|
| Purification | Protein A/G, purified from cell culture supernatant. |
|---|
| Accession | O60609 |
|---|
| Form | Liquid |
|---|
| Storage buffer | 0.01M PBS,pH7.4. |
|---|
| Stability and Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -702°C. |
|---|
| Alternate Names | REGN5069,CAS:2377679-19-9 |
|---|
| Background | Nadecnemab is an IgG4κ antibody targeting to GFRA3, glial cell derived neurotrophic factor family receptor alpha 3. Nadecnemab can be used for research of osteoarthritis of the knee/pain. |
|---|
| Note | For research use only. Not for use in clinical or therapeutic applications. |
|---|
